01 October 2010
A new drug form of blood coagulation factor IX: Red blood cell-entrapped factor IX
Elena Ivanovna SinauridzeABCDEF, Tatyana Alekseevna VuimoBF, Elena Viktorovna KulikovaB, Igor Igorevich ShmyrevB, Fazoil Inoyatovich AtaullakhanovAGMed Sci Monit 2010; 16(10): PI19-26 :: ID: 881179
Abstract
Background: Deficiency of factor IX causes hemophilia B, and primary treatment for hemophilia B is based on recurrent infusions of deficient factor IX. Frequent infusions of foreign protein diminish patients’ quality of life, and increase the risk of development of immune reaction. We entrapped factor IX into erythrocytes-carriers (pharmacocytes) to prolong the drug’s circulation life time, and to prevent immune response to the drug.
Material/Methods: Factor IX was biotynilated by standard method and then loaded aseptically into volunteers’ erythrocytes with our gentle procedure of stepwise dialysis. The comparison of pharmacokinetics for free and autologous erythrocytes-entrapped biotinylated factor IX (FIXbiot) was done. Concentrations of factor IXbiot in plasma and lysates of erythrocytes were quantitatively assessed with a sandwich ELISA.
Results: Stepwise dialysis method allowed stable loading of factor IXbiot into erythrocytes. Elimination of the loaded erythrocytes followed the first-order kinetics. The mean half-time of elimination for free FIXbiot was 8.8±5.6 hours, and for RBC-entrapped factor IXbiot 73.9±16.0 hours. Elimination of FIXbiot from plasma did not follow the first order kinetics because this factor concentration depended not only on the rate of its elimination, but also on the rate of factor appearance in plasma as a result of pharmackocytes’ degradation. A rough estimate of the feasibility of the approach was done.
Conclusions: The life time of the erythrocyte-based form of FIXbiot in the circulation is significantly (5–10 times) prolonged compared with its free form, suggesting that this form has potential clinical applications.
Keywords: Kinetics, Hemophilia B - therapy, Feasibility Studies, Factor IX - therapeutic use, Erythrocytes, Drug Carriers, Biotinylation, Technology, Pharmaceutical, young adult
Editorial
01 February 2025 : Editorial
Editorial: Current Approaches to Screening for Lung Cancer in Smokers and Non-SmokersDOI: 10.12659/MSM.948255
Med Sci Monit 2025; 31:e948255
In Press
Clinical Research
Pre- and Post-Surgical MRI Analysis of Levator Ani in Pelvic Organ Prolapse Patients: A Single-Center StudyMed Sci Monit In Press; DOI: 10.12659/MSM.945993
Clinical Research
Comparative Impact of Kinesio Taping and Post-Isometric Muscle Relaxation on Pain and Myofascial Mechanics ...Med Sci Monit In Press; DOI: 10.12659/MSM.945376
Clinical Research
Surgical Efficacy in Varicocele Ligation with Ephedrine-Assisted Blood Pressure ControlMed Sci Monit In Press; DOI: 10.12659/MSM.946234
Clinical Research
Retrospective Study to Compare Injury Patterns and Associations in 170 Patients Following Electric Scooter ...Med Sci Monit In Press; DOI: 10.12659/MSM.947155
Most Viewed Current Articles
17 Jan 2024 : Review article 6,968,277
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 701,791
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 25,442
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 20,020
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912